Antigenic Specificity of Immunoprotective Therapeutic Vaccination for Glaucoma

Bakalash, Sharon; Kessler, Anat; Mizrahi, Tal; Nussenblatt, Robert B.; Schwartz, Michal

doi:10.1167/iovs.03-0080

Cited by 80 publications

(61 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was recently suggested that this compound can activate a wide range of self-reactive T cells (20,21). In a model of a chronic neurodegenerative disorder associated with optic nerve neuropathy, such as glaucoma, Cop-1 vaccination was found to bypass the tissue-specificity barrier imposed by antigens residing in the damaged tissue (15,22) and to significantly increase neuronal survival (15,20).…”

mentioning

confidence: 99%

Therapeutic vaccine for acute and chronic motor neuron diseases: Implications for amyotrophic lateral sclerosis

Angelov

Waibel

Guntinas‐Lichius

et al. 2003

Proc. Natl. Acad. Sci. U.S.A.

179

104

View full text Add to dashboard Cite

Therapeutic vaccination with Copaxone (glatiramer acetate, Cop-1) protects motor neurons against acute and chronic degenerative conditions. In acute degeneration after facial nerve axotomy, the number of surviving motor neurons was almost two times higher in Cop-1-vaccinated mice than in nonvaccinated mice, or in mice injected with PBS emulsified in complete Freund's adjuvant (P < 0.05). In mice that express the mutant human gene Cu͞Zn superoxide dismutase G93A (SOD1), and therefore simulate the chronic human motor neuron disease amyotrophic lateral sclerosis, Cop-1 vaccination prolonged life span compared to untreated matched controls, from 211 ؎ 7 days (n ‫؍‬ 15) to 263 ؎ 8 days (n ‫؍‬ 14; P < 0.0001). Our studies show that vaccination significantly improved motor activity. In line with the experimentally based concept of protective autoimmunity, these findings suggest that Cop-1 vaccination boosts the local immune response needed to combat destructive self-compounds associated with motor neuron death. Its differential action in CNS autoimmune diseases and neurodegenerative disorders, depending on the regimen used, allows its use as a therapy for either condition. Daily administration of Cop-1 is an approved treatment for multiple sclerosis. The protocol for non-autoimmune neurodegenerative diseases such as amyotrophic lateral sclerosis, remains to be established by future studies.

show abstract

mentioning

confidence: 99%

Therapeutic vaccine for acute and chronic motor neuron diseases: Implications for amyotrophic lateral sclerosis

Angelov

Waibel

Guntinas‐Lichius

et al. 2003

Proc. Natl. Acad. Sci. U.S.A.

179

104

View full text Add to dashboard Cite

show abstract

“…For instance, copolymer-1 could be used as a vaccine as it is an antigen that cross responds with a widespread array of T-cells, and can provoke a defensive immune reaction to shield retinal ganglion cells from cell mortality initiated by toxins or improved Intra ocular Pressure (Bakalash et al, 2003). A fundamental concern for planning neuro-defensive vaccines is the position of protection.…”

Section: Neuro Defensive Vaccinesmentioning

confidence: 99%

“…A fundamental concern for planning neuro-defensive vaccines is the position of protection. Some recommended that the focus should be in the retinal ganglion cells and not in the optical nerves because in the initial glaucomatous phase cell fatality stimulated by higher intra ocular pressure that arises in the retinal ganglion cells, not in the optical nerve (Bakalash et al, 2003). R16, a peptide derivative from the retinal ganglion cell, is one paradigm of a neuro-protecting vaccine.…”

Section: Neuro Defensive Vaccinesmentioning

confidence: 99%

See 1 more Smart Citation

Molecular basis of glaucoma and its therapeutical analysis in Pakistan: an overview

et al. 2017

View full text Add to dashboard Cite

The human eye is an organ of vision. It plays a prime role in life, gives us the sense of sight, and enables to understand about the world around us. Visualization and interpretation of colors, shapes and dimensions of numerous objects is made possible by eye. Inherited eye diseases comprise 1/3 of all reported human genetic disorders. This review will focus on Glaucoma which comprises a predictable visual illnesses concerning optic nerve deterioration and if remains without any cure can result in failure in eyesight. The optical nerve injure comprises deterioration of the retinal ganglion cells (RGCs). Glaucoma represents a heterogeneous group of optic neuropathies with a complex genetic basis. These neuropathies gradually reduce vision without warning and often without symptoms. Different forms of glaucoma share some common clinical manifestations that usually include specific abnormal appearance of the optic nerve head, characteristic loss of visual field and chronic painless progression. Glaucoma is a progressive optical neuropathy considered by optical disc changes, nerve fiber film break, and visual field defects. Present-day treatment preferences predominantly targeting at reducing IOP by making use of pharmaceutical means, laser treatment and surgical procedure. Developed conducts target neuroprotection with vaccines, the hang-up of NO synthesis and apoptosis. Attaining a better appreciative of the pathogenesis can support in the improvement of novel handling options and, perhaps, even a remedy for glaucoma. There are more than 1.8million glaucoma patients in Pakistan and almost half of them have already lost their eyesight, permanently, due to delay in diagnosis and treatment. About 90% population in the country has no awareness about this disease, resultantly; more and more people are becoming permanently blind in Pakistan due to untreated glaucoma.

show abstract

“…R 16, a peptide derived from the RGC, is one example of a neuroprotective vaccine. Although R16 can cause slight RGC death for those without glaucoma, the benefit from this treatment far exceeded the damage from untreated glaucoma conditions (21).…”

Section: Neuroprotective Vaccinesmentioning

confidence: 99%

Glaucoma: Current and Developing Concepts for Inflammation, Pathogenesis and Treatment

et al. 2006

View full text Add to dashboard Cite

Glaucoma is a prevalent neurodegenerative disorder of the eye. However, the mechanism leading to the disease is still unclear. Increased intraocular pressure (lOP) and subsequent retinal ganglion cell (RGC) death leading to the loss of visual field characterizes the pathology of primary open angle glaucoma, which is the most common form. Possible factors leading to glaucoma include glutamateinduced neurotoxicity, nitric oxide (NO) based damage, disruption of neurotrophic factor transport and immune-induced neurodestruction. Current treatment options primarily aim at decreasing lOP by utilizing pharmacological agents, laser therapy and surgery. Developing treatments target neuroprotection with vaccines, the inhibition of NO synthesis and apoptosis. Gaining a better understanding of the pathogenesis can aid in the development of new treatment options and, perhaps, even a cure for glaucoma.

show abstract

Antigenic Specificity of Immunoprotective Therapeutic Vaccination for Glaucoma

Cited by 80 publications

References 37 publications

Therapeutic vaccine for acute and chronic motor neuron diseases: Implications for amyotrophic lateral sclerosis

Therapeutic vaccine for acute and chronic motor neuron diseases: Implications for amyotrophic lateral sclerosis

Molecular basis of glaucoma and its therapeutical analysis in Pakistan: an overview

Glaucoma: Current and Developing Concepts for Inflammation, Pathogenesis and Treatment

Contact Info

Product

Resources

About